At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 17, 2026 at 18:59 ET
Biogen announced the acquisition of private biotech RayThera for up to $1 billion (upfront plus milestone payments), adding early-stage small-molecule immunology assets. The lead candidate is expected to enter Phase 1 in Q3 2026, and the deal is anticipated to close in Q3 2026. At ~3.5% of Biogen's market cap, this is a modest bolt-on pipeline expansion with no near-term revenue impact.
- Total potential deal value up to $1 billion, consisting of upfront payment and clinical/regulatory milestone payments
- RayThera's lead candidate expected to enter Phase 1 development in early Q3 2026
- Transaction expected to close in Q3 2026, subject to customary conditions and regulatory approvals
- RayThera is a private San Diego-based small molecule immunology company that recently completed a Series A financing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access